Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse - Methamphetamine and 3,4-methylenedioxymethamphetamine

Protein Science

Volumn 18, Issue 11, 2009, Pages 2336-2345

  Celikel, Reha ^a   Peterson, Eric C ^a   Owens, S Michael ^a   Varughese, Kottayil I ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Antimethamphetamine antibody; Crystal structure; Methamphetamine; scFv; Therapeutic antibody

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CARBON; CARBOXYLIC ACID; CATION; GLUTAMIC ACID; HISTIDINE; METHAMPHETAMINE; MONOCLONAL ANTIBODY; NITROGEN; OXYGEN;

ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; CRYSTAL STRUCTURE; HYDROGEN BOND; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STEREOISOMERISM;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; BINDING SITES, ANTIBODY; HYDROPHOBICITY; IMMUNOGLOBULIN VARIABLE REGION; METHAMPHETAMINE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN BINDING; STREET DRUGS; WATER;

EID: 70350492289     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.244     Document Type: Article

References (34)

1. NDIC (2008) National drug treatment summary. Johnstown, PA: National Drug Intelligence Center.
2. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, Van MG, Bangala Y, Guessous I, Muller P, Willers J, Maurer P, Bachmann MF, Cerny T (2008) A vaccine against nicotine for smoking cessation: A randomized controlled trial. PLoS ONE 3(6):e2547.
3. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR (2005) Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 58:158-164. (Pubitemid 41008133)
4. Kosten T, Owens SM (2005) Immunotherapy for the treatment of drug abuse. Pharmacol Ther 108:76-85.
5. Gentry WB, Laurenzana EM, Williams DK, West JR, Berg RJ, Terlea T, Owens SM (2006) Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol 6:968-977.
6. Peterson EC, Gunnell M, Che Y, Goforth RL, Carroll FI, Henry R, Liu H, Owens SM (2007) Using hapten design to discover therapeuticmonoclonal antibodies for treating methamphetamine abuse. J Pharmacol Exp Ther 322:30-39. (Pubitemid 46956367)
7. Poljak RJ (1973) X-ray crystallographic studies of immunoglobulins. Contemp Top Mol Immunol 2:1-26.
8. Byrnes-Blake KA, Carroll FI, Abraham P, Owens SM (2001) Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. Int Immunopharmacol 1:329-338. (Pubitemid 32183731)
9. Goel A, Colcher D, Baranowska-Kortylewicz J, Augustine S, Booth BJ, Pavlinkova G, Batra SK (2000) Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res 60:6964-6971. (Pubitemid 32059170)
10. Peterson EC, Laurenzana EM, Atchley WT, Hendrickson HP, Owens SM (2008) Development and preclinical testing of a high-affinity single-chain antibody against (+)- methamphetamine. J Pharmacol Exp Ther 325:124-133.
11. Shelver WL, Keyler DE, Lin G, Murtaugh MP, Flickinger MC, Ross CA, Pentel PR (1996) Effects of recombinant drugspecific single chain antibody Fv fragment on [3H]-desipramine distribution in rats. Biochem Pharmacol 51:531-537.
12. Johnson G, Wu TT (2001) Kabat Database and its applications: future directions. Nucl Acids Res 29:205-206. (Pubitemid 32054448)
13. Hakey P, Quellette J, Zubieta J, Korter T (2008) Redetermination of (+)-methamphetamine hydrochloride at 90 K. Acta Crystallogr E64:940.
14. Morimoto BH, Lovel S, Kahr B (1998) Ecstasy: 3,4- methylenedioxymethamphetamine (MDMA). Acta Crystallogr C54:229-231.
15. Celikel R, Ruggeri ZM, Varughese KI (2000) von Willebrand factor conformation and adhesive function is modulated by an internalized water molecule. Nat Struct Biol 7:881-884. (Pubitemid 30786107)
16. Burley SK, Petsko GA (1985) Aromatic-aromatic interaction: a mechanism of protein structure stabilization. Science 229:23-28.
17. Burley SK, Petsko GA (1988) Weakly polar interactions in proteins. Adv Protein Chem 39:125-189.
18. Chelli R, Gervasio FL, Procacci P, Schettino V (2002) Stacking and T-shape competition in aromatic-aromatic amino acid interactions. J Am Chem Soc 124:6133-6143. (Pubitemid 34552857)
19. Burley SK, Petsko GA (1986) Amino-aromatic interactions in proteins. FEBS Lett 203:139-143.
20. Gallivan JP, Dougherty DA (1999) Cation-pi interactions in structural biology. Proc Natl Acad Sci USA 96:9459-9464.
21. Pozharski E, Wilson MA, Hewagama A, Shanafelt AB, Petsko G, Ringe D (2004) Anchoring a cationic ligand: the structure of the Fab fragment of the anti-morphine antibody 9B1 and its complex with morphine. J Mol Biol 337:691-697. (Pubitemid 38331982)
22. Steiner T, Saenger W (1993) The ordered water cluster in vitamin B12 coenzyme at 15 K is stabilized by C-H⋯O hydrogen bonds. Acta Crystallogr D Biol Crystallogr 49:592-593.
23. Wahl MC, Sundaralingam M (1997) C-H⋯O hydrogen bonding in biology. Trends Biochem Sci 22:97-102.
24. Jiang L, Lai L (2002) CH⋯O hydrogen bonds at protein- protein interfaces. J Biol Chem 277:37732-37740.
25. Scheiner S (2006) Contributions of NH⋯O and CH⋯O hydrogen bonds to the stability of beta-sheets in proteins. J Phys Chem B 110:18670-18679.
26. Panigrahi SK, Desiraju GR (2007) Strong and weak hydrogen bonds in the protein-ligand interface. Proteins 67:128-141. (Pubitemid 46340133)
27. Sarkhel S, Desiraju GR (2004) N-H⋯O, O-H⋯O, and C-H⋯O hydrogen bonds in protein-ligand complexes: strong and weak interactions in molecular recognition. Proteins 54:247-259.
28. Larsen NA, Zhou B, Heine A, Wirsching P, Janda KD, Wilson IA (2001) Crystal structure of a cocaine-binding antibody. J Mol Biol 311:9-15.
29. Pozharski E, Moulin A, Hewagama A, Shanafelt AB, Petsko GA, Ringe D (2005) Diversity in hapten recognition: structural study of an anti-cocaine antibody M82G2. J Mol Biol 349:570-582. (Pubitemid 40724567)
30. Lim K, Owens SM, Arnold L, Sacchettini JC, Linthicum DS (1998) Crystal structure of monoclonal 6B5 Fab complexed with phencyclidine. J Biol Chem 273:28576-28582. (Pubitemid 28507539)
31. Atwell JL, Breheney KA, Lawrence LJ, Mccoy AJ, Kortt AA, Hudson PJ (1999) scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng 12:597-604.
32. Volkel T, Korn T, Bach M, Muller R, Kontermann RE (2001) Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies. Protein Eng 14:815-823. (Pubitemid 34024665)
33. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326. (Pubitemid 27085611)
34. Brunger AT, Adams PD, Clore GM, Delano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS (1998) Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D 54:905-921. (Pubitemid 28443603)